Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 6,732 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: CHANGE Study Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.

NCT00192309
View directory record Official record
Conditions
Influenza
Interventions
CAIV-T, TIV, Placebo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 23, 2026, 10:30 AM EDT
Not listed Not applicable Interventional

Dual Joint Visual Feedback Gait Retraining in Pediatric Hemiplegic Cerebral Palsy

NCT05011201
View directory record Official record
Conditions
Hemiplegic Cerebral Palsy
Interventions
Dual Joint Visual Feedback without Scoring, Dual Joint Visual Feedback with Scoring
Device
Lead sponsor
Kessler Foundation
Other
Eligibility
7 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 23, 2026, 10:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Implant Primary Stability and Ridge Dimensional Changes Utilizing the Osseodensification Protocol

NCT05283928
View directory record Official record
Conditions
Dental Implants
Interventions
OsseoDensification (OD) protocol, standard drilling (SD) protocol (NobelReplace® Conical)
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
22 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 23, 2026, 10:30 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
58
States / cities
Fresno, California • San Diego, California • Santa Barbara, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 23, 2026, 10:30 AM EDT
Recruiting Not applicable Interventional

Changes of Soft Tissue Grafting: A Randomized Study

NCT05633511
View directory record Official record
Conditions
Gingival Recession
Interventions
Split Mouth Design
Procedure
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 23, 2026, 10:30 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

NCT04530565
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Echocardiography Test, Electrocardiography, Lumbar Puncture, Mesna, Methotrexate, Multigated Acquisition Scan, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
207
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 10:30 AM EDT
Recruiting Not applicable Interventional

Survivors Uniting for Remote Guided Exercise

NCT07290309
View directory record Official record
Conditions
Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Physical Activity, Physical Activity Behavior, Cancer (With or Without Metastasis), Cancer - Chronic Lymphocytic Leukemia, Cancer - Ovarian
Interventions
Virtually Supervised Exercise Sessions, Asynchronous Group
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 23, 2026, 10:30 AM EDT
Completed Not applicable Interventional Results available

Complex Sleep Apnea Syndrome (CompSAS) Resolution Study

NCT00915499
View directory record Official record
Conditions
Complex Sleep Apnea Syndrome
Interventions
VPAP Adapt SV
Device
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Phoenix, Arizona • Chicago, Illinois • Skokie, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Oct 23, 2026, 10:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute Alcohol Response In Bipolar Disorder: a fMRI Study

NCT04063384
View directory record Official record
Conditions
Bipolar Disorder, Alcohol Drinking, Alcohol Use Disorder
Interventions
alcohol beverage, Placebo beverage
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
21 Years to 26 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 23, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Results available

Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study

NCT00431834
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Cardioblate System Surgical Ablation System, Surgical RF Ablation
Device · Procedure
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
15
States / cities
Phoenix, Arizona • Concord, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2013 · Synced Oct 23, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Results available

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

NCT00671034
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Pharmacological Study, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 30 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 23, 2026, 10:30 AM EDT
Terminated Phase 1 Interventional

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

NCT02070406
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cyclophosphamide, fludarabine phosphate, NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL, dendritic cell vaccine therapy, aldesleukin, fludeoxyglucose F 18, positron emission tomography, laboratory biomarker analysis
Drug · Biological · Radiation + 2 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
16 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 23, 2026, 10:30 AM EDT
Terminated Phase 2 Interventional Results available

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

NCT01229111
View directory record Official record
Conditions
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Unresectable Adult Primary Liver Cancer, Periampullary Adenocarcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
Interventions
cediranib maleate, oxaliplatin, leucovorin calcium, fluorouracil
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Cleveland, Ohio • Columbus, Ohio • Mayfield Heights, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 23, 2026, 10:30 AM EDT
Completed Not applicable Interventional

Lifestyle Changes Through Exercise and Nutrition

NCT02863887
View directory record Official record
Conditions
Obesity, Diabetes
Interventions
Weight loss intervention
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 23, 2026, 10:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tracheostomy Change

NCT04105387
View directory record Official record
Conditions
Tracheostomy
Interventions
Early Tracheostomy Change
Procedure
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 2 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 23, 2026, 10:30 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

NCT02332980
View directory record Official record
Conditions
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Richter Syndrome, Waldenstrom Macroglobulinemia
Interventions
Ibrutinib, Idelalisib, Laboratory Biomarker Analysis, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 23, 2026, 10:30 AM EDT
Completed Phase 3 Interventional Results available

A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)

NCT00317642
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
clofarabine (IV formulation), placebo, cytarabine
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
55 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 23, 2026, 10:30 AM EDT
Completed No phase listed Observational

Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis

NCT03025269
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 23, 2026, 10:30 AM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04910568
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 10:30 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

NCT02709889
View directory record Official record
Conditions
Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma, Neuroendocrine Prostate Cancer, High Grade Gastroenteropancreatic Neuroendocrine Carcinoma, Other Neuroendocrine Carcinoma, Other Solid Tumors
Interventions
Rovalpituzumab tesirine, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 23, 2026, 10:30 AM EDT
Completed Not applicable Interventional

A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease

NCT01475760
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
K2CG chewing gum (20mg chitosan), K2CG chewing gum (60mg chitosan)
Other
Lead sponsor
Denver Nephrologists, P.C.
Other
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Tempe, Arizona • Denver, Colorado • Meridian, Idaho + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 23, 2026, 10:30 AM EDT
Completed Phase 2 Interventional Results available

Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

NCT03023046
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
Cyclophosphamide, Dasatinib, Doxorubicin, Etoposide, Imatinib Mesylate, Laboratory Biomarker Analysis, Prednisone, Rituximab, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 23, 2026, 10:30 AM EDT
Terminated Not applicable Interventional Results available

Women With Chest Pain and Normal Coronary Arteries Study

NCT00743197
View directory record Official record
Conditions
Chest Pain
Interventions
Aspirin, Lisinopril, Simvastatin, Lovaza, Therapeutic Lifestyle Changes
Drug · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 90 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 23, 2026, 10:30 AM EDT
Terminated Phase 2 Interventional Results available

AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer

NCT00427973
View directory record Official record
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
cediranib maleate, laboratory biomarker analysis, computed tomography, dynamic contrast-enhanced magnetic resonance imaging, pharmacological study
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Oct 23, 2026, 10:30 AM EDT